Andapsin may be available in the countries listed below.
Ingredient matches for Andapsin
Sucralfate
Sucralfate is reported as an ingredient of Andapsin in the following countries:
- Sweden
International Drug Name Search
Friday, 28 May 2010
Friday, 21 May 2010
Ambex
Ambex may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Ambex
Ambroxol
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Ambex in the following countries:
- Czech Republic
Levamisole
Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of Ambex in the following countries:
- Australia
- New Zealand
Niclosamide
Niclosamide is reported as an ingredient of Ambex in the following countries:
- Australia
- New Zealand
International Drug Name Search
Reduxal
Reduxal may be available in the countries listed below.
Ingredient matches for Reduxal
Sibutramine
Sibutramine hydrochloride monohydrate (a derivative of Sibutramine) is reported as an ingredient of Reduxal in the following countries:
- Dominican Republic
International Drug Name Search
Halopredone Acetate
Halopredone Acetate may be available in the countries listed below.
Ingredient matches for Halopredone Acetate
Halopredone
Halopredone Acetate (JAN, USAN) is also known as Halopredone (Rec.INN)
International Drug Name Search
Glossary
| JAN | Japanese Accepted Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Click for further information on drug naming conventions and International Nonproprietary Names.
Tuesday, 18 May 2010
Osmo-Adalat
Osmo-Adalat may be available in the countries listed below.
Ingredient matches for Osmo-Adalat
Nifedipine
Nifedipine is reported as an ingredient of Osmo-Adalat in the following countries:
- Georgia
- Israel
- Russian Federation
International Drug Name Search
Saturday, 15 May 2010
Ridoner
Ridoner may be available in the countries listed below.
Ingredient matches for Ridoner
Risperidone
Risperidone is reported as an ingredient of Ridoner in the following countries:
- Bulgaria
International Drug Name Search
Wednesday, 12 May 2010
Anausin Métoclopramide
Anausin Métoclopramide may be available in the countries listed below.
Ingredient matches for Anausin Métoclopramide
Metoclopramide
Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Anausin Métoclopramide in the following countries:
- France
International Drug Name Search
Sunday, 9 May 2010
Paracétamol Codéine Biogaran
Paracétamol Codéine Biogaran may be available in the countries listed below.
Ingredient matches for Paracétamol Codéine Biogaran
Codeine
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Paracétamol Codéine Biogaran in the following countries:
- France
Paracetamol
Paracetamol is reported as an ingredient of Paracétamol Codéine Biogaran in the following countries:
- France
International Drug Name Search
Mitratapide
In some countries, this medicine may only be approved for veterinary use.
Scheme
Rec.INN
CAS registry number (Chemical Abstracts Service)
0179602-65-4
Chemical Formula
C36-H41-Cl-N8-O4-S
Molecular Weight
717
Therapeutic Category
Dietary agent
Chemical Names
2-((2R)-Butan-2-yl)-4-(4-{4-(4-({(2S,4R)-2-(4-chlorphenyl)-2-((4-methyl-4H-1,2,4-triazol-3-ylsulfanyl)methyl)-1,3-dioxolan-4-yl}methoxy)phenyl)piperazin-1-yl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-on (IUPAC)
2-[(2R)-Butan-2-yl]-4-(4-{4-[4-({(2S,4R)-2-(4-chlorophenyl)-2-[(4-methyl-4H-1,2,4-triazol-3-ylsulfanyl)methyl]-1,3-dioxolan-4-yl}methoxy)phenyl]piperazin-1-yl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (WHO)
3H-1,2,4-triazol-3-one, (4-(4-(4-(4-(2S,4R)-2-(4-chlorophenyl)-2-(((4-methyl-4H-1,2,4-triazol-3-yl)thio)methyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl-2,4-dihydro-2-((1R)-1-methylpropyl)-
Foreign Names
- Mitratapidum (Latin)
- Mitratapid (German)
- Mitratapide (French)
- Mitratapida (Spanish)
Generic Name
- Mitratapide (OS: USAN)
Brand Names
- Yarvitan (veterinary use)
Boehringer Ingelheim, Sweden; Janssen Animal Health, Belgium; Janssen Animal Health, Germany; Janssen Animal Health, Netherlands; Janssen Cilag-D, Italy; Janssen Pharmaceutica, Austria; Janssen Santé Animale, France; Orion, Finland
International Drug Name Search
Glossary
| IUPAC | International Union of Pure and Applied Chemistry |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.
Rynatuss Tablets
carbetapentane tannate, chlorpheniramine tannate, ephedrine tannate, and phenylephrine tannate
Dosage Form: tablet
Rynatuss®
Tablets
IN-0717-16 Rev. 1/09
Description
RYNATUSS® Tablets are an antitussive/antihistamine/nasal decongestant/bronchodilator combination.
Each tablet contains:
Carbetapentane Tannate 60 mg
Chlorpheniramine Tannate 5 mg
Ephedrine Tannate 10 mg
Phenylephrine Tannate 10 mg
Other ingredients: corn starch, dibasic calcium phosphate, FD&C Blue No. 1, FD&C Red No. 40, magnesium stearate, methylcellulose, polygalacturonic acid, povidone, talc.
Clinical Pharmacology
RYNATUSS® Tablets combine the antitussive action of carbetapentane, the sympathomimetic decongestant effect of phenylephrine, the antihistaminic action of chlorpheniramine, and the bronchodilator action of ephedrine.
Indications and Usage
RYNATUSS® Tablets are indicated for the symptomatic relief of cough associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis. Appropriate therapy should be provided for the primary disease.
Contraindications
RYNATUSS® Tablets are contraindicated for newborns, nursing mothers, and patients who are sensitive to any of the ingredients or related compounds.
Warnings
Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, narrow angle glaucoma, or prostatic hypertrophy. Do not use in patients taking monoamine oxidase (MAO) inhibitors, or for 14 days after stopping treatment with an MAOI.
This product contains an antihistamine which may cause drowsiness and may have additive central nervous system (CNS) effects with alcohol or other CNS depressants (e.g., hypnotics, sedatives, tranquilizers).
Precautions
General: Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients. Antihistamines may cause excitation, particularly in children, but their combination with sympathomimetics may cause either mild stimulation or mild sedation.
Information for patients: Caution patients against drinking alcoholic beverages or engaging in potentially hazardous activities requiring alertness, such as driving a car or operating machinery, while using this product. Patients should be warned not to use this product if they are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If patients are uncertain whether a prescription drug contains an MAOI, they should be instructed to consult a health professional before taking such a product.
Drug interactions: MAO inhibitors may prolong and intensify the anticholinergic effects of antihistamines and the overall effects of sympathomimetic agents.
Carcinogenesis, mutagenesis, impairment of fertility: No long term animal studies have been performed with RYNATUSS® Tablets.
Pregnancy: Teratogenic effects: Pregnancy Category C. Animal reproduction studies have not been conducted with RYNATUSS® Tablets. It is also not known whether RYNATUSS® Tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RYNATUSS® Tablets should be given to a pregnant woman only if clearly needed.
Nursing mothers: RYNATUSS® Tablets should not be administered to a nursing woman.
Adverse Reactions
To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Adverse effects associated with RYNATUSS® Tablets at recommended doses have been minimal. The most common have been drowsiness, sedation, dryness of mucous membranes, and gastrointestinal effects. Serious side effects with oral antihistamines or sympathomimetics have been rare.
Overdosage
Signs and symptoms: May vary from CNS depression to stimulation (restlessness to convulsions). Antihistamine overdosage in young children may lead to convulsions and death. Atropine-like signs and symptoms may be prominent.
Treatment: Induce vomiting if it has not occurred spontaneously. Precautions must be taken against aspiration especially in infants, children, and comatose patients. If gastric lavage is indicated, isotonic or half-isotonic saline solution is preferred. Stimulants should not be used. If hypotension is a problem, vasopressor agents may be considered.
Dosage and Administration
Administer the recommended dose every 12 hours.
RYNATUSS® Tablets: Adults — 1 to 2 tablets.
How Supplied
RYNATUSS® Tablets are mauve, capsule-shaped, scored on one side and imprinted RYNATUSS 717 on the other side, containing in each tablet: carbetapentane tannate 60 mg, chlorpheniramine tannate 5 mg, ephedrine tannate 10 mg, phenylephrine tannate 10 mg, available in bottles of 100 (NDC 0037-0717-92).
Storage: Store at controlled room temperature 20°-25°C (68°-77°F).
Dispense in a tight container.
Protect from moisture.
Produced under license from
JFC Technologies
Bound Brook, NJ, U.S.A.
U.S. Patents 5,599,846; 5,663,415
To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
MEDA Pharmaceuticals®
Meda Pharmaceuticals Inc.
Somerset, New Jersey 08873-4120
Printed in U.S.A. Rev. 1/09
Package Label - Principal Display Panel – 100 Tablet Bottle
NDC 0037-0717-92
100 Tablets
RYNATUSS®
(carbetapentane tannate,
chlorpheniramine tannate,
ephedrine tannate,
phenylephrine tannate)
Each tablet contains:
Carbetapentane Tannate 60 mg
Chlorpheniramine Tannate 5 mg
Ephedrine Tannate 10 mg
Phenylephrine Tannate 10 mg
Rx Only
MEDA Pharmaceuticals™
LB-071701-09 Rev. 2/08
Usual Dosage: See package insert.
Store at controlled room temperature
20°-25°C (68°-77°F).
Protect from moisture.
Dispense in a tight container.
Tablet shade may vary among
lots; identity and purity of drug
are unaffected.
Produced under license from
JFC Technologies
Bound Brook, NJ U.S.A.
U.S. Patents 5,599,846; 5,663,415
MEDA Pharmaceuticals™
Meda Pharmaceuticals Inc.
Somerset, New Jersey 08873-4120
| RYNATUSS carbetapentane tannate, chlorpheniramine tannate, ephedrine tannate, and phenylephrine tannate tablet | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved drug other | 06/01/1960 | 01/31/2012 | |
| Labeler - Meda Pharmaceuticals Inc. (051229602) |
More Rynatuss Tablets resources
- Rynatuss Tablets Side Effects (in more detail)
- Rynatuss Tablets Dosage
- Rynatuss Tablets Use in Pregnancy & Breastfeeding
- Drug Images
- Rynatuss Tablets Drug Interactions
- Rynatuss Tablets Support Group
- 0 Reviews for Rynatusss - Add your own review/rating
Compare Rynatuss Tablets with other medications
- Cold Symptoms
- Nasal Congestion
- Sinus Symptoms
Tuesday, 4 May 2010
Metoprolol Basics
Metoprolol Basics may be available in the countries listed below.
Ingredient matches for Metoprolol Basics
Metoprolol
Metoprolol tartrate (a derivative of Metoprolol) is reported as an ingredient of Metoprolol Basics in the following countries:
- Germany
International Drug Name Search
Subscribe to:
Posts (Atom)